Cerus Co. (NASDAQ:CERS) saw some unusual options trading on Monday. Traders acquired 924 put options on the stock. This represents an increase of 1,201% compared to the typical daily volume of 71 put options.

CERS stock opened at $5.30 on Wednesday. Cerus has a twelve month low of $3.35 and a twelve month high of $8.05. The stock has a market cap of $777.50 million, a P/E ratio of -9.46 and a beta of 1.54. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.17 and a current ratio of 3.48.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, November 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). Cerus had a negative return on equity of 68.90% and a negative net margin of 74.95%. The business had revenue of $15.40 million for the quarter, compared to the consensus estimate of $15.40 million. During the same period last year, the business earned ($0.12) earnings per share. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. On average, sell-side analysts predict that Cerus will post -0.43 earnings per share for the current fiscal year.

In other Cerus news, CFO Kevin Dennis Green sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $7.50, for a total transaction of $375,000.00. Following the transaction, the chief financial officer now directly owns 110,825 shares in the company, valued at $831,187.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 58,349 shares of company stock worth $427,571. Corporate insiders own 6.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Cerus during the first quarter worth about $107,000. First Quadrant L P CA acquired a new stake in Cerus during the third quarter worth about $112,000. Advisory Services Network LLC acquired a new stake in Cerus during the second quarter worth about $130,000. Paloma Partners Management Co acquired a new stake in Cerus during the second quarter worth about $150,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in Cerus during the second quarter worth about $183,000. 58.69% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently issued reports on the company. BidaskClub downgraded Cerus from a “sell” rating to a “strong sell” rating in a research report on Friday, October 12th. Zacks Investment Research downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price target on shares of Cerus in a research report on Thursday, August 2nd. Finally, Cowen set a $10.00 price target on Cerus and gave the company a “buy” rating in a research report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/11/14/cerus-target-of-unusually-high-options-trading-cers.html.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Recommended Story: How to calculate compound interest

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.